<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01835197</url>
  </required_header>
  <id_info>
    <org_study_id>B7451001</org_study_id>
    <nct_id>NCT01835197</nct_id>
  </id_info>
  <brief_title>First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects</brief_title>
  <official_title>A Phase 1, Within Cohort, Randomized, Double Blind, Third-Party Open, Placebo-Controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-04965842 In Healthy Western and Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single- and multiple-ascending dose study is the first evaluation of PF-04965842, a
      Janus kinase1 (JAK1) inhibitor, in humans. The goal is to assess the safety, tolerability,
      pharmacokinetics and pharmacodynamics in healthy Western and Japanese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline vital signs (blood pressure, pulse rate, oral temperature and respiration rate) and physical examinations</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in 12 lead ECG parameters</measure>
    <time_frame>6 weeks</time_frame>
    <description>Quantitative changes in ECG intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of treatment emergent adverse events and withdrawals due to treatment emergent adverse events</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and magnitude of treatment emergent clinical laboratory abnormalities including hematology (with white blood cell count differentials, platelets, PT and aPTT), chemistry, fasting glucose, urinalysis</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in immunoglobulin levels</measure>
    <time_frame>6 weeks</time_frame>
    <description>Quantitative IgG, IgA, IgM, and IgE levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour urine creatinine clearance (Single Ascending Dose Period)</measure>
    <time_frame>Baseline, Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour urine creatinine clearance (Multiple Ascending Dose Period)</measure>
    <time_frame>Baseline, Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complement Level: C3</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement Level: C4</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement Level: C3A</measure>
    <time_frame>6 weeks</time_frame>
    <description>Cohorts 1-7 and Cohort 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement Level: Bb</measure>
    <time_frame>6 weeks</time_frame>
    <description>Cohorts 1-7 and Cohort 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose: Dose-normalized Area Under the Curve From Time Zero to Infinity (AUCinf(dn))</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose: Accumulation Ratio based on Cmax (Rac(Cmax))</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Pharmacokinetics; for twice-a-day dosing, amount of PF-0496842 excreted unchanged in 12 hours (AE12)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Pharmacokinetics; for twice-a-day dosing, percent of PF-0496842 excreted unchanged in 12 hours (AE12%)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose: Apparent Volume of Distribution at Steady State (Vz/F)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Vz/F is the distribution of a drug between plasma and the rest of the body following oral adminstration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose: Apparent Total Body Clearance (CL/F)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Pharmacokinetics; for once-a-day dosing, amount of PF-0496842 excreted unchanged in 24 hours (AE24)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Pharmacokinetics; for once-a-day dosing, percent of PF-0496842 excreted unchanged in 24 hours (AE24%)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLr)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-Sensitivity C-Reactive Protein (hsCRP)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil counts</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocyte counts</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement Level: CH50</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose: Apparent Total Body Clearance (CL/F)</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose: Dose-normalized Maximum Observed Plasma Concentration (Cmax(dn))</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose: Area Under the Curve to the end of the dosing period (AUCtau(dn))</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose: Accumulation Ratio based on AUC predicted (Rss)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose: Accumulation Ration based on AUC observed (Rac)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose: Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one-half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose: Peak to Trough Fluctuation (PTF)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose: Dose-normalized Area Under the Curve to the end of the dosing period (AUCtau(dn))</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose: Area Under the Curve From Time Zero to Infinity (AUCinf)</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose: Dose-normalized Maximum Observed Plasma Concentration (Cmax(dn))</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose: Area Under the Curve to the end of the dosing period (AUCtau)</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose: Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast(dn))</measure>
    <time_frame>8 days</time_frame>
    <description>Dose-normalized area under the plasma concentration time-curve from zero to the last measured concentration (AUClast(dn))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose: Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>8 days</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Ascending Dose: Area Under the Curve to the end of the dosing period (AUCtau)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose: Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Ascending Dose: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SAD Cohorts 1-8 Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohorts 1-8 Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohorts 3 through 5 Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohorts 3 through 5 Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohorts 6 and 7 Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohorts 6 and 7 Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 8 Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 8 Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 9 Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 9 Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04965842</intervention_name>
    <description>Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.</description>
    <arm_group_label>SAD Cohorts 1-8 Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.</description>
    <arm_group_label>SAD Cohorts 1-8 Placebo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04965842</intervention_name>
    <description>Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.</description>
    <arm_group_label>MAD Cohorts 3 through 5 Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.</description>
    <arm_group_label>MAD Cohorts 3 through 5 Placebo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04965842</intervention_name>
    <description>Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.</description>
    <arm_group_label>MAD Cohorts 6 and 7 Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.</description>
    <arm_group_label>MAD Cohorts 6 and 7 Placebo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04965842</intervention_name>
    <description>Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.</description>
    <arm_group_label>MAD Cohort 8 Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.</description>
    <arm_group_label>MAD Cohort 8 Placebo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04965842</intervention_name>
    <description>Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.</description>
    <arm_group_label>MAD Cohort 9 Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.</description>
    <arm_group_label>MAD Cohort 9 Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.

          -  Females must be of non-child bearing potential and either at least 1 year post
             menopausal (FSH ≥40 IU/L), or have documented hysterectomy (with or without bilateral
             oophrectomy) at least 6 months prior to study day

          -  Subjects willing to defer receiving prophylactic immunizations (e.g. influenza or
             pneumococcal vaccines) during the study.

          -  Absolute lymphocyte count must be greater than or equal to the lower limit of the
             laboratory reference range.

          -  Subjects enrolled in Cohort 8 must have four Japanese grandparents born in Japan.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, , pulmonary,
             gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic
             disease (including drug allergies, but excluding untreated, asymptomatic, seasonal
             allergies at time of dosing).

          -  History of hepatitis or positive testing for human immunodeficiency virus (HIV),
             hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBc Ab) or hepatitis C
             antibodies (HCV).

          -  Clinically significant abnormality on chest X-ray performed at screening or within 3
             months of screening date; or history of tuberculosis or active or latent or
             inadequately treated infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7451001&amp;StudyName=First-in-Human%20Study%20to%20Evaluate%20Safety%20and%20Tolerability%20of%20Single%20and%20Multiple%20Ascending%20Doses%20of%20Janus%20Kinase-1%20Inhibitor%20PF-04965842%20in</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2013</study_first_submitted>
  <study_first_submitted_qc>April 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2013</study_first_posted>
  <last_update_submitted>June 19, 2014</last_update_submitted>
  <last_update_submitted_qc>June 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Randomized</keyword>
  <keyword>Double Blind</keyword>
  <keyword>Placebo-Controlled</keyword>
  <keyword>Single- &amp; Multiple Dose Escalation</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>PK</keyword>
  <keyword>PD</keyword>
  <keyword>Pf-04965842</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

